|  Help  |  About  |  Contact Us

Search our database by keyword

Examples

  • Search this entire website. Enter identifiers, names or keywords for genes, diseases, strains, ontology terms, etc. (e.g. Pax6, Parkinson, ataxia)
  • Use OR to search for either of two terms (e.g. OR mus) or quotation marks to search for phrases (e.g. "dna binding").
  • Boolean search syntax is supported: e.g. Balb* for partial matches or mus AND NOT embryo to exclude a term

Search results 1 to 100 out of 569 for Pcsk9

<< First    < Previous  |  Next >    Last >>
0.04s

Categories

Hits by Pathway

Hits by Strain

Hits by Category

Type Details Score
Gene
255738 | PCSK9
Type: gene
Organism: human
•
•
•
•
•
Gene
424664 | PCSK9
Type: gene
Organism: chicken
•
•
•
•
•
Gene
100150316 | pcsk9
Type: gene
Organism: zebrafish
•
•
•
•
•
Gene
717147 | PCSK9
Type: gene
Organism: macaque, rhesus
•
•
•
•
•
Gene
102152231 | PCSK9
Type: gene
Organism: dog, domestic
•
•
•
•
•
Gene
100484989 | pcsk9
Type: gene
Organism: frog, western clawed
•
•
•
•
•
Gene
298296 | Pcsk9
Type: gene
Organism: rat
•
•
•
•
•
Gene
456880 | PCSK9
Type: gene
Organism: chimpanzee
•
•
•
•
•
Protein Coding Gene
MGI:2140260 | Pcsk9
Type: protein_coding_gene
Organism: mouse, laboratory
•
•
•
•
•
Publication
24506872 | J:210649
First Author: Gustafsen C
Year: 2014
Journal: Cell Metab
Title: The hypercholesterolemia-risk gene SORT1 facilitates PCSK9 secretion.
Volume: 19
Issue: 2
Pages: 310-8
•
•
•
•
•
Publication
28600283 | J:247994
First Author: Berger JM
Year: 2017
Journal: J Lipid Res
Title: Inhibition of PCSK9 does not improve lipopolysaccharide-induced mortality in mice.
Volume: 58
Issue: 8
Pages: 1661-1669
•
•
•
•
•
Publication
35720337 | J:326042
 
First Author: Zou Y
Year: 2022
Journal: Front Immunol
Title: Targeting PCSK9 Ameliorates Graft Vascular Disease in Mice by Inhibiting NLRP3 Inflammasome Activation in Vascular Smooth Muscle Cells.
Volume: 13
Pages: 894789
•
•
•
•
•
Publication
26092101 | J:258762
First Author: Ding Z
Year: 2015
Journal: Cardiovasc Res
Title: Cross-talk between LOX-1 and PCSK9 in vascular tissues.
Volume: 107
Issue: 4
Pages: 556-67
•
•
•
•
•
Publication
28894089 | J:253103
First Author: Gustafsen C
Year: 2017
Journal: Nat Commun
Title: Heparan sulfate proteoglycans present PCSK9 to the LDL receptor.
Volume: 8
Issue: 1
Pages: 503
•
•
•
•
•
Publication
22481440 | J:186215
First Author: Kysenius K
Year: 2012
Journal: Cell Mol Life Sci
Title: PCSK9 regulates neuronal apoptosis by adjusting ApoER2 levels and signaling.
Volume: 69
Issue: 11
Pages: 1903-16
•
•
•
•
•
Publication
32615123 | J:304016
First Author: Garshick MS
Year: 2021
Journal: J Invest Dermatol
Title: Characterization of PCSK9 in the Blood and Skin of Psoriasis.
Volume: 141
Issue: 2
Pages: 308-315
•
•
•
•
•
Publication
24916110 | J:246618
First Author: Ding Q
Year: 2014
Journal: Circ Res
Title: Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing.
Volume: 115
Issue: 5
Pages: 488-92
•
•
•
•
•
Publication
36880401 | J:337944
First Author: Laudette M
Year: 2023
Journal: Cardiovasc Res
Title: Cardiomyocyte-specific PCSK9 deficiency compromises mitochondrial bioenergetics and heart function.
Volume: 119
Issue: 7
Pages: 1537-1552
•
•
•
•
•
Publication
34280453 | J:319428
 
First Author: François M
Year: 2021
Journal: J Lipid Res
Title: PCSK9 is not secreted from mature differentiated intestinal cells.
Volume: 62
Pages: 100096
•
•
•
•
•
Publication
18354138 | J:137556
First Author: Grefhorst A
Year: 2008
Journal: J Lipid Res
Title: Plasma PCSK9 preferentially reduces liver LDL receptors in mice.
Volume: 49
Issue: 6
Pages: 1303-11
•
•
•
•
•
Publication
29180444 | J:257489
First Author: Sun H
Year: 2018
Journal: J Lipid Res
Title: PCSK9 deficiency reduces atherosclerosis, apolipoprotein B secretion, and endothelial dysfunction.
Volume: 59
Issue: 2
Pages: 207-223
•
•
•
•
•
Publication
30582457 | J:295085
First Author: Spolitu S
Year: 2019
Journal: Circ Res
Title: Hepatic Glucagon Signaling Regulates PCSK9 and Low-Density Lipoprotein Cholesterol.
Volume: 124
Issue: 1
Pages: 38-51
•
•
•
•
•
Publication
29593095 | J:264012
First Author: Lebeau P
Year: 2018
Journal: J Biol Chem
Title: Loss-of-function PCSK9 mutants evade the unfolded protein response sensor GRP78 and fail to induce endoplasmic reticulum stress when retained.
Volume: 293
Issue: 19
Pages: 7329-7343
•
•
•
•
•
Publication
30044755 | J:302051
First Author: Essalmani R
Year: 2018
Journal: Biol Chem
Title: A single domain antibody against the Cys- and His-rich domain of PCSK9 and evolocumab exhibit different inhibition mechanisms in humanized PCSK9 mice.
Volume: 399
Issue: 12
Pages: 1363-1374
•
•
•
•
•
Publication
23580231 | J:198477
 
First Author: Chen XW
Year: 2013
Journal: Elife
Title: SEC24A deficiency lowers plasma cholesterol through reduced PCSK9 secretion.
Volume: 2
Pages: e00444
•
•
•
•
•
Publication
17080197 | J:114949
First Author: Lagace TA
Year: 2006
Journal: J Clin Invest
Title: Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice.
Volume: 116
Issue: 11
Pages: 2995-3005
•
•
•
•
•
Publication
35981632 | J:328547
 
First Author: Marku A
Year: 2022
Journal: Metabolism
Title: Pancreatic PCSK9 controls the organization of the β-cell secretory pathway via LDLR-cholesterol axis.
Volume: 136
Pages: 155291
•
•
•
•
•
Publication
28495363 | J:256002
First Author: Fu T
Year: 2017
Journal: Biochim Biophys Acta
Title: APP, APLP2 and LRP1 interact with PCSK9 but are not required for PCSK9-mediated degradation of the LDLR in vivo.
Volume: 1862
Issue: 9
Pages: 883-889
•
•
•
•
•
Publication
28515357 | J:280541
 
First Author: Lai Q
Year: 2017
Journal: JCI Insight
Title: E2F1 inhibits circulating cholesterol clearance by regulating Pcsk9 expression in the liver.
Volume: 2
Issue: 10
•
•
•
•
•
Publication
26824363 | J:234032
First Author: Levenson AE
Year: 2016
Journal: Endocrinology
Title: Effect of Leptin Replacement on PCSK9 in ob/ob Mice and Female Lipodystrophic Patients.
Volume: 157
Issue: 4
Pages: 1421-9
•
•
•
•
•
Publication
19878649 | J:155603
First Author: Langhi C
Year: 2009
Journal: Biochem Biophys Res Commun
Title: PCSK9 is expressed in pancreatic delta-cells and does not alter insulin secretion.
Volume: 390
Issue: 4
Pages: 1288-93
•
•
•
•
•
Publication
22426206 | J:184553
First Author: Ai D
Year: 2012
Journal: J Clin Invest
Title: Regulation of hepatic LDL receptors by mTORC1 and PCSK9 in mice.
Volume: 122
Issue: 4
Pages: 1262-70
•
•
•
•
•
Publication
28758421 | J:321141
First Author: Baragetti A
Year: 2017
Journal: Eur J Prev Cardiol
Title: PCSK9 deficiency results in increased ectopic fat accumulation in experimental models and in humans.
Volume: 24
Issue: 17
Pages: 1870-1877
•
•
•
•
•
Publication
25320235 | J:225776
First Author: Walley KR
Year: 2014
Journal: Sci Transl Med
Title: PCSK9 is a critical regulator of the innate immune response and septic shock outcome.
Volume: 6
Issue: 258
Pages: 258ra143
•
•
•
•
•
Publication
23614904 | J:200728
First Author: Parker RA
Year: 2013
Journal: J Lipid Res
Title: Bile acid and sterol metabolism with combined HMG-CoA reductase and PCSK9 suppression.
Volume: 54
Issue: 9
Pages: 2400-9
•
•
•
•
•
Publication
33992809 | J:307091
First Author: Peyot ML
Year: 2021
Journal: Biochim Biophys Acta Mol Cell Biol Lipids
Title: Substantial PCSK9 inactivation in β-cells does not modify glucose homeostasis or insulin secretion in mice.
Volume: 1866
Issue: 8
Pages: 158968
•
•
•
•
•
Publication
30768966 | J:295268
 
First Author: Wang M
Year: 2019
Journal: Metabolism
Title: Role of PCSK9 in lipid metabolic disorders and ovarian dysfunction in polycystic ovary syndrome.
Volume: 94
Pages: 47-58
•
•
•
•
•
Publication
37845353 | J:342661
First Author: Roychowdhury T
Year: 2023
Journal: Nat Genet
Title: Genome-wide association meta-analysis identifies risk loci for abdominal aortic aneurysm and highlights PCSK9 as a therapeutic target.
Volume: 55
Issue: 11
Pages: 1831-1842
•
•
•
•
•
Publication
18660751 | J:138995
First Author: Jonas MC
Year: 2008
Journal: EMBO Rep
Title: PCSK9 is required for the disposal of non-acetylated intermediates of the nascent membrane protein BACE1.
Volume: 9
Issue: 9
Pages: 916-22
•
•
•
•
•
Publication
32673528 | J:318017
First Author: Garçon D
Year: 2020
Journal: Arterioscler Thromb Vasc Biol
Title: Circulating Rather Than Intestinal PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) Regulates Postprandial Lipemia in Mice.
Volume: 40
Issue: 9
Pages: 2084-2094
•
•
•
•
•
Publication
16407292 | J:118822
First Author: Costet P
Year: 2006
Journal: J Biol Chem
Title: Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c.
Volume: 281
Issue: 10
Pages: 6211-8
•
•
•
•
•
Publication
25652089 | J:331029
First Author: Shende VR
Year: 2015
Journal: J Lipid Res
Title: Reduction of circulating PCSK9 and LDL-C levels by liver-specific knockdown of HNF1α in normolipidemic mice.
Volume: 56
Issue: 4
Pages: 801-9
•
•
•
•
•
Publication
18675252 | J:140041
First Author: Shan L
Year: 2008
Journal: Biochem Biophys Res Commun
Title: PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide.
Volume: 375
Issue: 1
Pages: 69-73
•
•
•
•
•
Publication
36733269 | J:333029
 
First Author: Pärn A
Year: 2022
Journal: Front Mol Neurosci
Title: PCSK9 deficiency alters brain lipid composition without affecting brain development and function.
Volume: 15
Pages: 1084633
•
•
•
•
•
Publication
32423823 | J:322678
First Author: Kamada Y
Year: 2020
Journal: Biochem Biophys Res Commun
Title: Loss of core fucosylation reduces low-density lipoprotein receptor expression in hepatocytes by inducing PCSK9 production.
Volume: 527
Issue: 3
Pages: 682-688
•
•
•
•
•
Publication
34118252 | J:331531
 
First Author: Wang B
Year: 2021
Journal: J Lipid Res
Title: Atherosclerosis-associated hepatic secretion of VLDL but not PCSK9 is dependent on cargo receptor protein Surf4.
Volume: 62
Pages: 100091
•
•
•
•
•
Publication
31731717 | J:289959
 
First Author: Gu L
Year: 2019
Journal: Molecules
Title: Lunasin Improves the LDL-C Lowering Efficacy of Simvastatin via Inhibiting PCSK9 Expression in Hepatocytes and ApoE-/- Mice.
Volume: 24
Issue: 22
•
•
•
•
•
Publication
26980204 | J:252584
First Author: Tavori H
Year: 2016
Journal: Cardiovasc Res
Title: Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms.
Volume: 110
Issue: 2
Pages: 268-78
•
•
•
•
•
Publication
28504688 | J:312651
First Author: Kumar S
Year: 2017
Journal: Lab Invest
Title: Accelerated atherosclerosis development in C57Bl6 mice by overexpressing AAV-mediated PCSK9 and partial carotid ligation.
Volume: 97
Issue: 8
Pages: 935-945
•
•
•
•
•
Publication
15741654 | J:99809
First Author: Lalanne F
Year: 2005
Journal: J Lipid Res
Title: Wild-type PCSK9 inhibits LDL clearance but does not affect apoB-containing lipoprotein production in mouse and cultured cells.
Volume: 46
Issue: 6
Pages: 1312-9
•
•
•
•
•
Publication
26323289 | J:227085
First Author: Roubtsova A
Year: 2015
Journal: J Lipid Res
Title: PCSK9 deficiency unmasks a sex- and tissue-specific subcellular distribution of the LDL and VLDL receptors in mice.
Volume: 56
Issue: 11
Pages: 2133-42
•
•
•
•
•
Publication
27470509 | J:246692
First Author: Lu H
Year: 2016
Journal: Arterioscler Thromb Vasc Biol
Title: Hypercholesterolemia Induced by a PCSK9 Gain-of-Function Mutation Augments Angiotensin II-Induced Abdominal Aortic Aneurysms in C57BL/6 Mice-Brief Report.
Volume: 36
Issue: 9
Pages: 1753-7
•
•
•
•
•
Publication
29800228 | J:268233
First Author: Ding Z
Year: 2018
Journal: Cardiovasc Res
Title: PCSK9 expression in the ischaemic heart and its relationship to infarct size, cardiac function, and development of autophagy.
Volume: 114
Issue: 13
Pages: 1738-1751
•
•
•
•
•
Publication
20562239 | J:164461
First Author: Ishibashi M
Year: 2010
Journal: J Lipid Res
Title: Reduced VLDL clearance in Apoe(-/-)Npc1(-/-) mice is associated with increased Pcsk9 and Idol expression and decreased hepatic LDL-receptor levels.
Volume: 51
Issue: 9
Pages: 2655-63
•
•
•
•
•
Publication
20453200 | J:164465
First Author: Liu M
Year: 2010
Journal: J Lipid Res
Title: PCSK9 is not involved in the degradation of LDL receptors and BACE1 in the adult mouse brain.
Volume: 51
Issue: 9
Pages: 2611-8
•
•
•
•
•
Publication
21518694 | J:174826
First Author: Rousselet E
Year: 2011
Journal: J Lipid Res
Title: PCSK9 reduces the protein levels of the LDL receptor in mouse brain during development and after ischemic stroke.
Volume: 52
Issue: 7
Pages: 1383-91
•
•
•
•
•
Publication
26494228 | J:242389
First Author: Demers A
Year: 2015
Journal: Arterioscler Thromb Vasc Biol
Title: PCSK9 Induces CD36 Degradation and Affects Long-Chain Fatty Acid Uptake and Triglyceride Metabolism in Adipocytes and in Mouse Liver.
Volume: 35
Issue: 12
Pages: 2517-25
•
•
•
•
•
Publication
35985474 | J:328536
First Author: Roubtsova A
Year: 2022
Journal: Biochim Biophys Acta Mol Cell Biol Lipids
Title: PCSK9 deficiency results in a specific shedding of excess LDLR in female mice only: Role of hepatic cholesterol.
Volume: 1867
Issue: 12
Pages: 159217
•
•
•
•
•
Publication
24808179 | J:216624
First Author: Ly K
Year: 2014
Journal: J Biol Chem
Title: Annexin A2 reduces PCSK9 protein levels via a translational mechanism and interacts with the M1 and M2 domains of PCSK9.
Volume: 289
Issue: 25
Pages: 17732-46
•
•
•
•
•
Publication
34809446 | J:340930
First Author: Guo Y
Year: 2022
Journal: Arterioscler Thromb Vasc Biol
Title: PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Triggers Vascular Smooth Muscle Cell Senescence and Apoptosis: Implication of Its Direct Role in Degenerative Vascular Disease.
Volume: 42
Issue: 1
Pages: 67-86
•
•
•
•
•
Publication
31553664 | J:306860
First Author: Ben Djoudi Ouadda A
Year: 2019
Journal: Arterioscler Thromb Vasc Biol
Title: Ser-Phosphorylation of PCSK9 (Proprotein Convertase Subtilisin-Kexin 9) by Fam20C (Family With Sequence Similarity 20, Member C) Kinase Enhances Its Ability to Degrade the LDLR (Low-Density Lipoprotein Receptor).
Volume: 39
Issue: 10
Pages: 1996-2013
•
•
•
•
•
Publication
32750454 | J:302684
First Author: Molina-Jijon E
Year: 2020
Journal: Kidney Int
Title: Secretion of the epithelial sodium channel chaperone PCSK9 from the cortical collecting duct links sodium retention with hypercholesterolemia in nephrotic syndrome.
Volume: 98
Issue: 6
Pages: 1449-1460
•
•
•
•
•
Publication
22261195 | J:196628
First Author: Denis M
Year: 2012
Journal: Circulation
Title: Gene inactivation of proprotein convertase subtilisin/kexin type 9 reduces atherosclerosis in mice.
Volume: 125
Issue: 7
Pages: 894-901
•
•
•
•
•
Publication
21147780 | J:169483
First Author: Essalmani R
Year: 2011
Journal: J Biol Chem
Title: In vivo evidence that furin from hepatocytes inactivates PCSK9.
Volume: 286
Issue: 6
Pages: 4257-63
•
•
•
•
•
Publication
18666258 | J:169834
First Author: Zaid A
Year: 2008
Journal: Hepatology
Title: Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration.
Volume: 48
Issue: 2
Pages: 646-54
•
•
•
•
•
Publication
20026049 | J:157666
First Author: Mbikay M
Year: 2010
Journal: FEBS Lett
Title: PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities.
Volume: 584
Issue: 4
Pages: 701-6
•
•
•
•
•
Publication
29084995 | J:256633
First Author: Wang H
Year: 2017
Journal: Sci Rep
Title: Proprotein convertase subtilisin/kexin type 9 (PCSK9) Deficiency is Protective Against Venous Thrombosis in Mice.
Volume: 7
Issue: 1
Pages: 14360
•
•
•
•
•
Publication
36180774 | J:334768
First Author: Venugopal J
Year: 2022
Journal: Sci Rep
Title: Amiodarone improves anemia in a murine model of sickle cell disease and is associated with increased erythrocyte bis(monoacylglycerol) phosphate.
Volume: 12
Issue: 1
Pages: 16437
•
•
•
•
•
Publication
31366894 | J:285993
First Author: Schuster S
Year: 2019
Journal: Sci Rep
Title: Anti-PCSK9 antibodies inhibit pro-atherogenic mechanisms in APOE*3Leiden.CETP mice.
Volume: 9
Issue: 1
Pages: 11079
•
•
•
•
•
Publication
29438441 | J:258010
First Author: Kawakami R
Year: 2018
Journal: PLoS One
Title: Development of vaccine for dyslipidemia targeted to a proprotein convertase subtilisin/kexin type 9 (PCSK9) epitope in mice.
Volume: 13
Issue: 2
Pages: e0191895
•
•
•
•
•
Publication
31332258 | J:285609
First Author: Leung AKK
Year: 2019
Journal: Sci Rep
Title: Reduced Proprotein convertase subtilisin/kexin 9 (PCSK9) function increases lipoteichoic acid clearance and improves outcomes in Gram positive septic shock patients.
Volume: 9
Issue: 1
Pages: 10588
•
•
•
•
•
Publication
19265033 | J:161830
First Author: Le May C
Year: 2009
Journal: Arterioscler Thromb Vasc Biol
Title: Proprotein convertase subtilisin kexin type 9 null mice are protected from postprandial triglyceridemia.
Volume: 29
Issue: 5
Pages: 684-90
•
•
•
•
•
Publication
30395847 | J:318538
First Author: Luan C
Year: 2019
Journal: J Invest Dermatol
Title: Potentiation of Psoriasis-Like Inflammation by PCSK9.
Volume: 139
Issue: 4
Pages: 859-867
•
•
•
•
•
Publication
19443683 | J:150005
First Author: Chan JC
Year: 2009
Journal: Proc Natl Acad Sci U S A
Title: A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates.
Volume: 106
Issue: 24
Pages: 9820-5
•
•
•
•
•
Publication
17242417 | J:121673
First Author: Graham MJ
Year: 2007
Journal: J Lipid Res
Title: Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice.
Volume: 48
Issue: 4
Pages: 763-7
•
•
•
•
•
Publication
27358438 | J:245021
First Author: Haas ME
Year: 2016
Journal: Circulation
Title: The Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Nephrotic Syndrome-Associated Hypercholesterolemia.
Volume: 134
Issue: 1
Pages: 61-72
•
•
•
•
•
Publication
36207148 | J:331931
 
First Author: Leung AKK
Year: 2022
Journal: Atherosclerosis
Title: Modulation of vascular endothelial inflammatory response by proprotein convertase subtilisin-kexin type 9.
Volume: 362
Pages: 29-37
•
•
•
•
•
Publication
26628375 | J:323534
First Author: Poirier S
Year: 2015
Journal: Cell Rep
Title: GRP94 Regulates Circulating Cholesterol Levels through Blockade of PCSK9-Induced LDLR Degradation.
Volume: 13
Issue: 10
Pages: 2064-71
•
•
•
•
•
Publication
32244519 | J:301023
 
First Author: Cawley NX
Year: 2020
Journal: Int J Mol Sci
Title: Evaluation of the Potential Role of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Niemann-Pick Disease, Type C1.
Volume: 21
Issue: 7
•
•
•
•
•
Publication
33020528 | J:299080
First Author: Venugopal J
Year: 2020
Journal: Sci Rep
Title: Non-hematopoietic deficiency of proprotein convertase subtilisin/kexin type 9 deficiency leads to more severe anemia in a murine model of sickle cell disease.
Volume: 10
Issue: 1
Pages: 16514
•
•
•
•
•
Publication
27279328 | J:269180
 
First Author: Milasan A
Year: 2016
Journal: Sci Rep
Title: Effects of LDL Receptor Modulation on Lymphatic Function.
Volume: 6
Pages: 27862
•
•
•
•
•
Publication
15805190 | J:97836
First Author: Rashid S
Year: 2005
Journal: Proc Natl Acad Sci U S A
Title: Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9.
Volume: 102
Issue: 15
Pages: 5374-9
•
•
•
•
•
Publication
25621930 | J:281504
First Author: Berger JM
Year: 2015
Journal: Atherosclerosis
Title: PCSK9-deficiency does not alter blood pressure and sodium balance in mouse models of hypertension.
Volume: 239
Issue: 1
Pages: 252-9
•
•
•
•
•
Publication
28970592 | J:255760
First Author: Pan Y
Year: 2017
Journal: Sci Rep
Title: A Therapeutic Peptide Vaccine Against PCSK9.
Volume: 7
Issue: 1
Pages: 12534
•
•
•
•
•
Publication
18799458 | J:143101
First Author: Mayer G
Year: 2008
Journal: J Biol Chem
Title: Annexin A2 is a C-terminal PCSK9-binding protein that regulates endogenous low density lipoprotein receptor levels.
Volume: 283
Issue: 46
Pages: 31791-801
•
•
•
•
•
Publication
23675525 | J:200620
First Author: Canuel M
Year: 2013
Journal: PLoS One
Title: Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1).
Volume: 8
Issue: 5
Pages: e64145
•
•
•
•
•
Publication
30831144 | J:291920
 
First Author: Huang M
Year: 2019
Journal: Metabolism
Title: PAQR3 modulates blood cholesterol level by facilitating interaction between LDLR and PCSK9.
Volume: 94
Pages: 88-95
•
•
•
•
•
Publication
32913121 | J:300458
First Author: Wang D
Year: 2020
Journal: J Biol Chem
Title: Ascorbic acid enhances low-density lipoprotein receptor expression by suppressing proprotein convertase subtilisin/kexin 9 expression.
Volume: 295
Issue: 47
Pages: 15870-15882
•
•
•
•
•
Publication
27284008 | J:318423
First Author: Weider E
Year: 2016
Journal: J Biol Chem
Title: Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Single Domain Antibodies Are Potent Inhibitors of Low Density Lipoprotein Receptor Degradation.
Volume: 291
Issue: 32
Pages: 16659-71
•
•
•
•
•
Publication
28750079 | J:246449
First Author: Romagnuolo R
Year: 2017
Journal: PLoS One
Title: Roles of the low density lipoprotein receptor and related receptors in inhibition of lipoprotein(a) internalization by proprotein convertase subtilisin/kexin type 9.
Volume: 12
Issue: 7
Pages: e0180869
•
•
•
•
•
Publication
23690465 | J:211389
First Author: Tavori H
Year: 2013
Journal: Circulation
Title: Serum proprotein convertase subtilisin/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation.
Volume: 127
Issue: 24
Pages: 2403-13
•
•
•
•
•
Publication
22848640 | J:189694
First Author: Seidah NG
Year: 2012
Journal: PLoS One
Title: Annexin A2 is a natural extrahepatic inhibitor of the PCSK9-induced LDL receptor degradation.
Volume: 7
Issue: 7
Pages: e41865
•
•
•
•
•
Publication
22580899 | J:186176
First Author: Sun H
Year: 2012
Journal: Arterioscler Thromb Vasc Biol
Title: Proprotein convertase subtilisin/kexin type 9 interacts with apolipoprotein B and prevents its intracellular degradation, irrespective of the low-density lipoprotein receptor.
Volume: 32
Issue: 7
Pages: 1585-95
•
•
•
•
•
Publication
21273557 | J:184166
First Author: Roubtsova A
Year: 2011
Journal: Arterioscler Thromb Vasc Biol
Title: Circulating proprotein convertase subtilisin/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue.
Volume: 31
Issue: 4
Pages: 785-91
•
•
•
•
•
Publication
16794006 | J:129548
First Author: Lambert G
Year: 2006
Journal: Endocrinology
Title: Fasting induces hyperlipidemia in mice overexpressing proprotein convertase subtilisin kexin type 9: lack of modulation of very-low-density lipoprotein hepatic output by the low-density lipoprotein receptor.
Volume: 147
Issue: 10
Pages: 4985-95
•
•
•
•
•
Publication
26547624 | J:317703
First Author: Ma D
Year: 2015
Journal: J Biol Chem
Title: The Liver Clock Controls Cholesterol Homeostasis through Trib1 Protein-mediated Regulation of PCSK9/Low Density Lipoprotein Receptor (LDLR) Axis.
Volume: 290
Issue: 52
Pages: 31003-12
•
•
•
•
•
Publication
23974119 | J:203942
First Author: Tao R
Year: 2013
Journal: J Biol Chem
Title: FoxO3 transcription factor and Sirt6 deacetylase regulate low density lipoprotein (LDL)-cholesterol homeostasis via control of the proprotein convertase subtilisin/kexin type 9 (Pcsk9) gene expression.
Volume: 288
Issue: 41
Pages: 29252-9
•
•
•
•
•
Publication
34508778 | J:312366
First Author: Susan-Resiga D
Year: 2021
Journal: J Biol Chem
Title: Asialoglycoprotein receptor 1 is a novel PCSK9-independent ligand of liver LDLR cleaved by furin.
Volume: 297
Issue: 4
Pages: 101177
•
•
•
•
•
Publication
24675665 | J:222901
First Author: Sasaki M
Year: 2014
Journal: Arterioscler Thromb Vasc Biol
Title: Hepatic overexpression of idol increases circulating protein convertase subtilisin/kexin type 9 in mice and hamsters via dual mechanisms: sterol regulatory element-binding protein 2 and low-density lipoprotein receptor-dependent pathways.
Volume: 34
Issue: 6
Pages: 1171-8
•
•
•
•
•
Publication
27121620 | J:253996
First Author: Tavori H
Year: 2016
Journal: Circ Res
Title: PCSK9 Association With Lipoprotein(a).
Volume: 119
Issue: 1
Pages: 29-35
•
•
•
•
•




MouseMine is a collaboration between MGI at The Jackson Laboratory and the InterMine project at the Cambridge Systems Biology Centre. MouseMine is funded through a grant from the NIH/NHGRI.The Jackson Laboratory makes no representation about the suitability or accuracy of this software or data for any purpose, and makes no warranties, either express or implied, including merchantability and fitness for a particular purpose or that the use of this software or data will not infringe any third party patents, copyrights, trademarks, or other rights. the software and data are provided "as is". This software and data are provided to enhance knowledge and encourage progress in the scientific community and are to be used only for research and educational purposes. Any reproduction or use for commercial purpose is prohibited without the prior express written permission of the Jackson Laboratory.

Copyright © 2017 by The Jackson Laboratory. All Rights Reserved

© 2002 - 2017 Department of Genetics, University of Cambridge, Downing Street,
Cambridge CB2 3EH, United Kingdom